Clinical Performance of the Elecsys CSF pTau181/Aβ42 Ratio for Concordance with Tau-PET in Two Independent Cohorts
The Elecsys CSF pTau<sub>181</sub>/Aβ<sub>42</sub> ratio may be a reliable tool for identifying tau pathology in clinical practice.
Authors
- Myrto Andreadou (ORCID: https://orcid.org/0000-0001-6757-4664)
- Sebastian Palmqvist (ORCID: https://orcid.org/0000-0002-9267-1930)
- Erik Stomrud (ORCID: https://orcid.org/0000-0002-0841-5580)
- Mattéo Tonietto (ORCID: https://orcid.org/0000-0001-9591-5710)
- Ruben Smith (ORCID: https://orcid.org/0000-0001-7147-0112)
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Samantha C. Burnham (ORCID: https://orcid.org/0000-0003-4805-5193)
- Clara Quijano‐Rubio (ORCID: https://orcid.org/0000-0001-9050-3282)
- Leslie M. Shaw (ORCID: https://orcid.org/0000-0002-7650-1210)
- Gregory Klein
- Christopher M. Rank
Institutions
- Roche (Switzerland) (CH)
- Eli Lilly (United States) (US)
- Lund University (SE)
- Roche Pharma AG (Germany) (DE)
- Institute for Neurodegenerative Disorders (US)
- Skåne University Hospital (SE)
- University of Pennsylvania (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1007/s40120-025-00798-8
- Citations
- 2
- Primary Topic
- Medical Imaging Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- Eli Lilly and Company
- University of Pennsylvania